细胞因子诱导的杀伤细胞治疗中晚期妇科肿瘤的临床研究

Clinical study on the treatment of patients with advanced gynecological oncology by cytokine-induced killer cells

目的评估细胞因子诱导的杀伤细胞（CIK细胞）过继免疫疗法治疗中晚期妇科肿瘤的临床疗效。方法参照美国斯坦福大学骨髓移植中心建立的CIK细胞培养方法诱导扩增CIK细胞。培养14d后分次回输给病人，观察病人治疗前后瘤体、肿瘤标志物、免疫指标、临床症状、生活质量、卡氏评分等变化，同时记录生存期。结果在32例接受CIK细胞治疗的中晚期妇科肿瘤病人中，CR＋PR＋MR为28例，总缓解率为87．5％，随访1a生存率为90．6％，2a生存率为81．3％，3a生存率为75．0％。临床症状治疗前、后有明显改善（P〈0．05）；生存质量卡氏评分提高率为78．1％；肿瘤标志物CA199有显著性差异（t=3．95，P〈0．05）；体重多数有增加。结论CIK细胞对为那些手术、放疗、化疗已无适应症的中晚期妇科肿瘤病人提供了一种可以继续延长生存期，提高生活质量的新途径。

Objective To estimate the clinical effects on patients with advanced gynecological oncology by cytokine-induced killer cells （CIK）. Methods CIK cells were induced by culturing PBMC of healthy people by incubation in vitro with IL-2, 7-IFN, anti-CD3 monoclonal antibody, and IL-1, and then were transfused back to the patients with advanced gynecological oncology after two weeks. The changes of tumor weight, life quality, immunity indexes, tumor markers （TM） and the Karnofsky＇s grade were observed. Results The effective rate of CIK was 87.5% （28/32） after a follow-up 3 year. The survival rate was 90.6% after 1 year, 81.3% after 2 years, and 75.0% after 3 years. All the patients had no obvious side effects. The CA125 in patients with advanced gynecological oncology after transfused was significantly lower than that before transfused （t=-3.95 P〈0.05）, the Karnofsky＇s grade and survival period after transfused CIK were significantly superior to that before the transfused. Conclusions CIK cells therapy might enhance effect of the anti-cancer, improve survival quantity and prolong survival period, and it could provide a potent immune therapeutic strategy for patients with advanced gynecological oncology.